in Vivo Antibody Drug Evaluation

Home > in Vivo Antibody Drug Evaluation
In Vivo Efficacy Evaluation Service in Animal Models
in Vivo Antibody Drug Evaluation
In vivo efficacy evaluation plays a critical role in both fundamental research and therapeutic drug development. Jotbody provides a well-established in vivo pharmacology platform built around mouse tumor models, including spontaneous, induced, and transplanted tumor models. Among these, transplanted tumor models offer clear target relevance, strong growth consistency, shorter study timelines, broad tumor-type coverage, and high reproducibility. Based on the target mechanism, suitable tumor cell lines and mouse strains are selected for tumor inoculation and dosing, followed by systematic monitoring of tumor growth and treatment response. With customized model development completed in as fast as 4 weeks, a broad portfolio of reference antibodies and cell lines, and highly consistent tumor model batches, the platform supports reliable and reproducible efficacy assessment with low intra-group variation.

Highlights

01

Diverse Mouse Strains and Disease Models

Dozens of transgenic and immunodeficient mouse strains, with 60+ tumor models covering major clinical cancer types.

02

Standardized Animal Facility and Management

SPF/Elite-grade and conventional clean animal facilities, operated in compliance with industry and animal ethics standards.

03

Customized One-Stop Services

Integrated support for antibody preparation, tumor cell line development, and customized small-animal efficacy studies.

04

Extensive Project Experience

Hundreds of projects across ADCs, antibodies, proteins, and targets in immunity, autoimmunity, and metabolism.

05

Rapid Delivery in 56 Days

56-day in vivo efficacy validation to accelerate PCC candidate selection.

Diverse Mouse Strains

Jotbody has successfully developed disease models using dozens of mouse and rat strains to support antibody drug evaluation. Appropriate animal strains are selected based on different target mechanisms and molecular modalities to enable tailored model development.
Animal Strains Target Mechanisms Molecular Modalities
C57BL/6
Balb/c
Nude Mice
CB-17 SCID
NOG
NCG
NSG
Transgenic Mice
SD/CD Rats 		Immune Checkpoints
Tumor Markers
Autoimmunity
Tumor Microenvironment
Angiogenesis
Immune Regulation
Cytokines 		ADCs
Monoclonal Antibodies
Multispecific Antibodies
Recombinant Proteins
mRNA
Small Molecules

60+ Established Tumor Models

As shown in Table 1, Jotbody has successfully developed 60+ tumor models, covering major clinical cancer types, including both hematologic and solid tumors.
Tumor Type Species Cell Line Tumor Cell Description Available Tumorigenicity
(WT / Nude / SCID)		 Tumorigenicity
(NCG / NOG / NSG)		 Growth Curve
Reference No.
Lymphoma Human Jeko-1 Human mantle cell lymphoma cells ✓ ✓ ✓ 1
Multiple Myeloma Human MM.1S Human myeloma cell line ✓ ✓ 2
Multiple Myeloma Human MOLP-8 Human multiple myeloma cells ✓ ✓ ✓ 3
Multiple Myeloma Human NCI-H929 Human myeloma cells ✓ ✓ 4
Lymphoma Human Romas Human B-cell lymphoma cells ✓ ✓ 5
Lymphoma Human Raji Human lymphoma cells ✓ ✓ ✓ 6
Gastric Cancer Human AGS Human gastric adenocarcinoma cells ✓ ✓ 7
Gastric Cancer Human NUGC-4 Human gastric cancer cells ✓ ✓ 8
Gastric Cancer Human NCI-N87 Human gastric cancer cells ✓ ✓ ✓ 9
Gastric Cancer Human SNU-16 Human gastric cancer cells ✓ ✓ 10
Colon Cancer Mouse CT-26 Mouse colon cancer cells ✓ ✓ 11
Colon Cancer Human COLO205 Human colon cancer cells ✓ ✓ 12
Colon Cancer Human HT29 Human colon cancer cells ✓ ✓ ✓ 13
Colon Cancer Mouse MC38 Mouse colon cancer cells ✓ ✓ 14
Pancreatic Cancer Human Aspc-1 Human metastatic pancreatic adenocarcinoma cells ✓ ✓ ✓ 16
Pancreatic Cancer Human Hs766T Human pancreatic cancer cells ✓ ✓ ✓ 18
Pancreatic Cancer Human SU.86.86 Human pancreatic ductal carcinoma cells ✓ ✓ ✓ 21
Liver Cancer Human HepG2 Human liver cancer cells ✓ ✓ ✓ 22
Lung Cancer Human HCC827 Human non-small cell lung cancer cells ✓ ✓ 23
Lung Cancer Human A549 Human non-small cell lung cancer cells ✓ ✓ 24
Breast Cancer Human MDA-MB-231 Human breast cancer cells ✓ ✓ ✓ 25
Breast Cancer Human JIMT-1 Human breast cancer cells ✓ ✓ 26
Breast Cancer Human BT474 Human breast ductal carcinoma cells ✓ ✓ 27
Ovarian Cancer Human SK-OV-3 Human ovarian cancer cells ✓ ✓ 28
Prostate Cancer Human PC-3 Human prostate cancer cells ✓ ✓ ✓ 29
Head and Neck Cancer Human A431 Human cutaneous squamous carcinoma cells ✓ ✓ 30
Oral Squamous Cell Carcinoma Human CAL-27 Human tongue squamous carcinoma cells ✓ ✓ 31
Pharyngeal Squamous Cell Carcinoma Human FaDu Human pharyngeal squamous carcinoma cells ✓ ✓ 32
Melanoma Human A375 Human malignant melanoma cells ✓ ✓ ✓ 33
Melanoma Human SK-MEL-5 Human malignant melanoma cells ✓ ✓ 34
Renal Cancer Human huCLDN18.2-HEK293 Human renal cancer cells ✓ ✓ ✓ 35
Gastric Cancer Human NUGC4-18.2 Human gastric cancer cells ✓ ✓ 36
Colon Cancer Mouse huCLDN18.2-MC-38 Mouse colon cancer cells ✓ ✓ 37 / 38
Colon Cancer Human PD-L1-Colo205 Human colon cancer cells ✓ ✓ 39
Prostate Cancer Human hu-Nectin-4-PC-3 Human prostate cancer cells ✓ ✓ ✓ 40
Ovarian Cancer Human CLDN6-OV90 Human ovarian cancer cells ✓ ✓ 41
Gastric Cancer Human PD-L1-NCI-N87 Human gastric cancer cells ✓ ✓ ✓ 42
Table 1. 60+ Established Tumor Models

The tumor cell lines used in these models show strong batch-to-batch consistency, high reproducibility, and low intra-group variation.
Representative tumor growth curves are shown below:

Extensive Experience in Target-Specific Animal Models

As shown in Table 2, Jotbody’s in vivo pharmacology platform has successfully completed efficacy evaluations for candidate molecules across dozens of high-interest targets in immunology, autoimmunity, and metabolism. The platform has also accumulated extensive project experience across multiple molecular modalities, including ADCs, monoclonal antibodies, bispecific/trispecific antibodies, and proteins.
Target MOA Study Solution 1 Study Solution 2 Reference Product 1 Reference Product 2
TIGIT Immune Checkpoint hTIGIT-mice A375-PBMC Reconstituted Model Tiragolumab
PVRIG Immune Checkpoint hPVRIG-mice PBMC Reconstituted Model COM701
TNFR2 Tumor Immunity hTNFR2-mice PBMC Reconstituted Model Opi Vi
CTLA-4 Immune Checkpoint hCTLA-4-mice PBMC Reconstituted Model Ipilimumab
EGFR RTKs A431 FaDu Cetuximab Panitumumab
4-1BB Tumor Immunity CT26 MC38 ABL111 ADG106
CD39 Tumor Immunity MOLP-8 TTX030
ROR1 ADC A549 MDA-MB-231 Cirmtuzumab
Trop2 ADC A431 MDA-MB-231 Sacituzumab
CLDN6 Tumor Marker PA-1 CLDN6-OV90 IMAB027
LAG3 Tumor Immunity hLAG3-mice PBMC Reconstituted Model Relatlimab HLX26
CD47 Tumor Immunity Raji SKOV-3 Magrolimab Lemzoparlimab
PD-L1 Immune Checkpoint hPD-L1-mice PBMC Reconstituted Model Atezolizumab Durvalumab
PD-1 Immune Checkpoint hPD-1-mice PBMC Reconstituted Model Pembrolizumab Nivolumab
VEGF Angiogenesis COLO-205 A431 Bevacizumab Ramucirumab
ANGPTL3 Cardiovascular DIO Obesity Model Evinacumab
ALX RTKs A549 MDA-MB-231 Enapotamab
DDR1 Tumor Immunity CT26 B16-F10 U.Texas
CLDN18.2 Tumor Marker MC38-hCLDN18.2 HEK293-hCLDN18.2 IMAB362
CD40 Tumor Immunity hCD40-mice Selicrelumab
HER2 RTKs BT474 N87 Trastuzumab Pertuzumab
CD24 Tumor Marker HT29 MCF-7 Tel Aviv U
CD100 Tumor Immunity CT-26 PBMC Reconstituted Model Pamrevlumab
TSLP Autoimmunity OVA Model Tezepelumab
BCMA Tumor Marker NCI-H929 MM.1S GSK2857916
Table 2. Jotbody Customized In Vivo Efficacy Study Solutions

Service Workflow

Service List

Service Service Content Client Provides Deliverables and Standards Timeline
Efficacy Evaluation
(Non-Prebuilt Model)
  1. Construction of overexpressing tumor cell lines
  2. Cell line quality control
  3. STR authentication
  4. Tumorigenicity development
  5. Efficacy model development and validation
  6. Efficacy evaluation
  1. Target information
  2. Antibody protein
  3. Study protocol
  1. Cell quality control data
  2. Tumor growth curves
  3. Final report
 6–8 weeks
Efficacy Evaluation
(Prebuilt Model) 		Efficacy evaluation
  1. Target information
  2. Antibody protein
  1. Growth curves
  2. Comprehensive analysis report
  3. Experimental report
 ~4 weeks
Multicolor Flow Cytometry Analysis Flow cytometric analysis of tissue/blood cell subpopulations Marker names Experimental report 1–3 days
Cytokine / Enzyme Detection
  1. Multiplex or single cytokine analysis
  2. Enzyme-related assays, etc.
 Marker names Experimental report 1–3 days
Pharmacokinetic Analysis
  1. PK study
  2. PK analysis
  1. Target information
  2. Antibody protein
 Experimental report 45 days